Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients with Diabetes and Cardiovascular Disease in Community Practice

Medicine & Life Sciences

• Sodium-Glucose Transport Proteins 100%
• Peptide Receptors 88%
• Cardiovascular Diseases 51%
• Type 2 Diabetes Mellitus 39%
• Dipeptidyl-Peptidase IV Inhibitors 11%
• Guidelines 11%
• Delivery of Health Care 10%
• Patient Acceptance of Health Care 10%
• Population 10%
• Electronic Health Records 9%
• Ambulatory Care 8%
• Secondary Prevention 8%
• Hispanic Americans 8%
• Chronic Renal Insufficiency 8%
• Chronic Kidney Failure 7%
• Cohort Studies 6%
• Retrospective Studies 5%
• Health Care Outcome Assessment 5%
• Glucose 5%
• Therapeutics 4%